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Abstract 
Background: Trastuzumab is a humanized monoclonal antibody (mAb) currently used for the treatment of breast 
cancer (BC) patients with HER-2 overexpressing tumor subtype. Previous data reported the involvement of FcγRIIIA/IIA 
gene polymorphisms and/or antibody-dependent cellular cytotoxicity (ADCC) in the therapeutic efficacy of trastu-
zumab, although results on these issues are still controversial. This study was aimed to evaluate in vitro the functional 
relationships among FcγRIIIA/IIA polymorphisms, ADCC intensity and HER-2 expression on tumor target cells and to 
correlate them with response to trastuzumab.
Patients and methods: Twenty-five patients with HER-2 overexpressing BC, receiving trastuzumab in a neoadjuvant 
(NEO) or metastatic (MTS) setting, were genotyped for the FcγRIIIA 158V>F and FcγRIIA 131H>R polymorphisms by a 
newly developed pyrosequencing assay and by multiplex Tetra-primer-ARMS PCR, respectively. Trastuzumab-medi-
ated ADCC of patients’ peripheral blood mononuclear cells (PBMCs) was evaluated prior to therapy and measured by 
51Chromium release using as targets three human BC cell lines showing different levels of reactivity with trastuzumab.
Results: We found that the FcγRIIIA 158F and/or the FcγRIIA 131R variants, commonly reported as unfavorable in BC, 
may actually behave as ADCC favorable genotypes, in both the NEO (P ranging from 0.009 to 0.039 and from 0.007 to 
0.047, respectively) and MTS (P ranging from 0.009 to 0.032 and P = 0.034, respectively) patients. The ADCC intensity 
was affected by different levels of trastuzumab reactivity with BC target cells. In this context, the MCF-7 cell line, show-
ing the lowest reactivity with trastuzumab, resulted the most suitable cell line for evaluating ADCC and response to 
trastuzumab. Indeed, we found a statistically significant correlation between an increased frequency of patients show-
ing ADCC of MCF-7 and complete response to trastuzumab in the NEO setting (P = 0.006).
Conclusions: Although this study was performed in a limited number of patients, it would indicate a correlation of 
FcγR gene polymorphisms to the ADCC extent in combination with the HER-2 expression levels on tumor target cells 
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Background
Leukocyte Fcγ receptors (FcγRs) are structurally related 
glycoproteins belonging to the immunoglobulin (Ig) 
superfamily, which bind the fragment C (Fc) region 
of IgG leading to FcγR aggregation at the cell surface 
and cell activation [1]. FcγRs are divided into 3 groups, 
FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) and 
subclasses, depending on their structural and func-
tional properties. FcγRI and FcγRII are expressed mainly 
by monocytes and macrophages, whereas FcγRIII is 
expressed by subsets of T cells and natural killer cells [2].
The most important function of the FcγRs is the regu-
lation of the immune response as, upon their engage-
ment, they can either stimulate or inhibit immune cell 
activation [2], suggesting that they can have a biological 
significance in the outcome of antibody-based therapies 
in tumors.
Among the functions mediated by activatory FcγRs, 
the antibody-dependent cellular cytotoxicity (ADCC), 
mediated by cells of the innate immunity, certainly plays 
an important role as it can contribute to eliminate tumor 
cells and, in some tumors, it may even represent the pre-
dominant effector of cell killing [3–6].
In the immunotherapy of HER-2 overexpressing BC, 
trastuzumab monoclonal antibody (mAb) may elicit 
ADCC upon binding to the HER-2 antigen region on 
tumor cells and with the Fc region to FcγRs on immune 
effector cells [7, 8]. This mechanism is similar to that of 
other mAbs of the IgG1 isotype, such as rituximab and 
cetuximab, upon binding to CD20 and EGFR, respec-
tively [9–12]. Such an interaction triggers the immune 
cell degranulation and activation, resulting in the lysis of 
antibody coated target cells.
However, only 20–30  % of HER-2-overexpressing 
patients respond to trastuzumab and a significant pro-
portion of them become resistant to the mAb [13].
The extent of in  vitro ADCC of BC cells mediated by 
trastuzumab may be influenced by several factors includ-
ing single nucleotide polymorphisms (SNPs) in the FcγR 
genes. It has been reported that these SNPs can alter the 
FcγR binding to the therapeutic mAbs and consequently 
the ADCC degree. In particular, the SNP rs396991 (G>T) 
corresponding to the substitution of valine (V) with phe-
nylalanine (F) at aminoacid position 158 of FcγRIIIA 
(158V>F variant) and the SNP rs1801274 (A>G) corre-
sponding to the substitution of histidine (H) with argi-
nine (R) at aminoacid position 131 of FcγRIIA (131H>R 
variant), appear to reduce the binding to the mAbs 
[14–16].
However, the association between FcγR polymor-
phisms and trastuzumab efficacy in BC is controversial. 
Indeed, the homozygous FcγRIIIA158V/V and FcγRIIA 
131H/H phenotypes (commonly identified as 158V/V and 
131H/H genotypes) have been associated with ADCC, 
response to trastuzumab and progression-free survival in 
two small retrospective studies [7, 17], whereas a larger 
study did not support these findings [18].
In the present study, we have investigated the 
FcγRIIIA158V>F and FcγRIIA131H>R genotype fre-
quencies in patients with BC overexpressing HER-2 and 
their role in the extent of in vitro trastuzumab-depend-
ent lysis of HER2-positive BC cells. We demonstrate that 
PBMCs from BC patients carrying the FcγRIIIA158F 
genotype can induce, in some circumstances, a more effi-
cient ADCC response than PBMCs carrying the homozy-
gous FcγRIIIA 158V/V genotype. We also demonstrate 
that the ADCC associated to particular FcγRIIIA and 
FcγRIIA genotypes can be influenced by the HER-2 
expression levels on target cells. In this context MCF-
7, a BC cell line showing the lowest HER-2 expression 
level, allowed us to point out a correlation between geno-




Women with histological diagnosis of locally advanced 
invasive or metastatic BC were considered eligible for 
the study if classified as HER-2 positive, i.e. score 3+ 
(by immuno-histochemical analysis: IHC) or IHC score 
2+ and FISH (fluorescence in situ hybridization) ampli-
fied. Twenty-five BC patients were enrolled in the study: 
15 patients in the neo-adjuvant setting (NEO) and 10 
patients in the metastatic setting (MTS).
In the NEO setting, all patients (with the exclusion of 
1 treated only with paclitaxel) were treated with FEC 
(fluorouracil, epirubicin and cyclophosphamide) for 4 
cycles followed by weekly paclitaxel for 12 weeks in com-
bination with trastuzumab. In the MTS setting, patients 
underwent a first line chemotherapy in combination with 
trastuzumab.
Response to trastuzumab was evaluated on the basis of 
clinical, pathological and radiologic examination of the 
tumor before and after treatment. In details, for the NEO 
in BC patients. However, to confirm our findings further experimental evidences obtained from a larger cohort of BC 
patients are mandatory.
Keywords: FcγR single nucleotide polymorphisms, ADCC, Trastuzumab, Breast cancer patients
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patients, pathological complete response (pCR) was used 
to evaluate the treatment response. pCR was assigned 
in absence of invasive residual carcinoma in the breast 
and/or at axillary lymph node level after surgery. In the 
presence of residual invasive carcinoma the response 
was considered partial (pPR). For the MTS patients, the 
revised RECIST criteria (version 1.1) were used to evalu-
ate the treatment response which was classified as stable 
disease (SD), partial response (PR), complete response 
(CR) and disease progression (PD).
This study was approved by the Ethics Committee of 
IRCCS AOU San Martino-IST, Genoa, Italy and written 
informed consent was obtained from each patient.
Thirty-three unrelated healthy Italian women (Trans-
fusion Service, Galliera Hospital, and IRCCS AOU San 
Martino-IST, Genoa, Italy), matched for patient’s age, 
were also included as a control population, upon written 
informed consent. In addition, a cohort of 64 unselected 
healthy donors were analyzed for FcγRIIIA and FcγRIIA 
genotyping and ADCC.
Genotyping of FcγRIIIA 158V>F and FcγRIIA 131H>R 
polymorphisms
Genotyping of FcγRIIIA 158V>F (rs396991) and FcγRIIA 
131H>R (rs1801274) variants was performed on genomic 
DNA by multiplex Tetra-Primer Amplification Refrac-
tory Mutation System (T-ARMS) PCR, direct sequenc-
ing (SBT) and pyrosequencing (PSQ). Genomic DNA 
was extracted from peripheral blood mononuclear cells 
(PBMCs) using a conventional proteinase K protocol, as 
previously described [19].
The FcγRIIIA was analyzed by PSQ and due to the high 
homology of FcγRIIIA with FcγRIIIB in the genomic 
region of interest, DNA samples were first amplified 
by primer pair specifically designed for it. To this aim, 
the PCR reaction was performed in a final volume of 
20 μl containing ≈25  ng genomic DNA, 1.5  mM  Mg2+ 
(5x buffer A and buffer B), 200 μmoli/L dNTPs, 0.8 μL 
Elongase® Enzyme Mix (Life Technologies) and 
0.5 μmol/L of each primers (Table 1).
PCR products were analyzed on 1 % agarose gel contain-
ing Eurosafe Nucleic Acid Stain (EuroClone, Milan, Italy) 
and the remaining amount was purified and diluted 1:20; 
then, to confirm specificity of FcγRIIIA amplification, a 
short amplicon was analyzed by direct sequencing (using 
the FcγRIIIA-F and FcγRIIIA-R-S primers (Table 1).
For the PSQ assay, a nested-PCR was setup by ampli-
fying 1 μl of diluted PCR products with the primer pair 
designed using the Pyrosequencing Assay Design soft-
ware (Biotage, Uppsala, Sweden) (Table 1).
The PSQ-PCR reactions were assembled with the 
EpMotion5070 liquid handling station (Eppendorf, Milan, 
Italy) in a final volume of 50  μl containing 200  µmol/l 
dNTPs, 1× GeneAmp buffer (1.5 mM MgCl2), 1.25U of 
Immolase Hot Start polymerase (Bioline, Milan, Italy) 
and 0.3  μM of the PCR primer pairs specific for the 
FcγRIIIA 158V>F SNP. The Pyro Gold reagent kit PSQ 
96MA was used for the sequencing reactions, according 
to the manufacturer instructions. The PSQ assay was per-
formed using a PSQ96MA instrument (Qiagen, Milan, 
Italy) and the sequencing analysis was conducted with 
the PSQTM 96MA (version 2.02) software.
The FcγRIIA 131H>R SNP was analyzed by T-ARMS 
PCR [20] and by PCR amplification followed by SBT [7] 
in both forward and reverse directions using previously 
described methods.
Both FcγRIIIA 158V>F and FcγRIIA 131H>R polymor-
phisms were independently re-tested in a different labo-
ratory by T-ARMS PCR or SBT, as previously described, 
and results where fully concordant.
Table 1 Primers and conditions for the analysis of FcγRIIIA gene polymorphism
a Genbank reference sequence: NG_009066.1; F forward, R reverse, Py pyrosequencing, S sequence, Bio biotinylated
b In italic, underlined, is indicated the deliberate mismatch, from the reference sequence, introduced to improve primer stability
c To increase the specificity of the FcγRIIIA amplification, the pyrosequencing primer was designed to include a cytosine (bold underlined) that is replaced by a 
thymidine in the FcγRIIIB gene (genebank reference sequence. NG_032926.1)
d Cycling conditions: 30″ at 94 °C followed by 35 cycles at 94 °C for 30″, 56 °C for 30″, 68 °C for 2′45″ and a final cycle at 70 °C for 10′
e Cycling conditions:10′ at 95 °C followed by 45 cycles at 95 °C for 30″, 57 °C for 30″, 72 °C for 30″ and a final cycle at 70 °C for 10′
f The polymorphism, in bold, is reported according to the IUB (International Union of Biochemistry) nomenclature




Py-FcγRIIIA-F Bio-AAAGCCACACTCAAAGACAGCc 122e MAAGCCCCCTGCAGAAGTAGf
Py-FcγRIIIA-R ATTCCAGGGTGGCACATGTC
Py-FcγRIIIA-S ACACATTTTTACTCCCAA
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Cell lines and culture conditions
The BC cell lines SKBR3, BT474 and MCF-7 (American 
Type Culture Collection; ATCC, Rockville, MD, USA) 
were maintained in monolayer culture in RPMI 1640 
medium supplemented with 10  % heat-inactivated FBS, 
5  mg/ml penicillin and 5  mg/ml streptomycin, 2  mM 
l-glutamine, at 37  °C in a humidified 5  % CO2 atmos-
phere and subcultured every 3–7  days. The leukaemic 
cell line K562 (ATCC) was grown in complete RPMI 1640 
culture medium. All reagents were purchased from Bio-
chrom KG (Berlin, Germany).
Analysis of trastuzumab reactivity by flow cytometry
For HER-2 cell surface staining with trastuzumab anti-
body (Herceptin; Roche, Basel, Switzerland), titration 
assays were performed by indirect immunofluorescence 
using as targets SKBR3, BT474 and MCF-7 cell lines. 
In particular, 2 ×  105 cells/sample were incubated with 
different concentrations (2, 0.2, 0.02, 2  ×  10−3 and 
2  ×  10−4  µg/ml) of the mAb for 30  min at 4  °C. After 
washing in FACS buffer, an Alexafluor 647-conjugated 
goat anti-human IgG secondary antibody (Molecular 
Probes, Inc. Eugene, OR, USA) was added and incubated 
for 30 min at 4 °C. After 2 washes, the cells were analyzed 
by flow cytometry on a CyAn-ADP-Flow-Cytometer 
(Beckman-Coulter); 5000 cellular events were analyzed 
per sample. Data were analyzed using Summit version 4.3 
Software (Beckman-Coulter).
Results were expressed as mean ratio of relative fluo-
rescence intensity (MRFI), calculated as follows: mean 
fluorescence intensity (MFI) of HER-2 staining/MFI of 
secondary antibody staining.
PBMC separation and antibody‑dependent cellular 
cytotoxicity (ADCC) assay
PBMCs were obtained after Ficoll-Hypaque density cen-
trifugation of blood samples derived from BC patients 
before starting trastuzumab treatment. In particular, the 
NEO PBMCs included 4 V/V carriers, 9 V/F or F/F car-
riers for the FcγRIIIA SNP and 3  H/H carriers, 10 H/R 
or R/R carriers for the FcγRIIA SNP. The MTS PBMCs 
included 3  V/V carriers, 6  V/F or F/F carriers for the 
FcγRIIIA SNP and 4 H/H carriers, 5 H/R or R/R carriers 
for the FcγRIIA SNP.
Ex-vivo isolated PBMCs were used as effector cells in 
the ADCC assay in the presence of trastuzumab. As in 
preliminary experiments we found that ADCC trigger-
ing could be effective in a wide range of trastuzumab 
concentrations (from 2 to 2  ×  10−4  µg/ml), we chose 
to perform all the cytolytic assays with trastuzumab at 
2  µg/ml (concentration at which the differences in tras-
tuzumab reactivity among target cell lines were more 
evident by flow cytometry). SKBR3, BT474 and MCF-7 
target cells were labelled with sodium 51Chromate (51Cr) 
and seeded in 96-V-bottomed microplates with effector 
cells (E)/target (T) at different E:T ratios in 200  µl of 
volume. Triplicate wells were set up for each E:T ratio 
and the percentage of lysis was calculated as previously 
described [21]. In details, the percent of specific cell lysis 
was calculated as [(experimental − spontaneous release)/
(maximum  −  spontaneous release)]  ×  100, in which 
spontaneous release refers to the 51Cr release of target 
cells incubated for 4 h without effector cells. The maxi-
mum release is the 51Cr release of each target cell in the 
presence of 1 N HCl. The maximum lysis was represented 
by the maximum − spontaneous release.
K562 cells were also used as HER-2 negative target 
cells. Basal cell lysis and ADCC were scored as present 
(≥5  % of lysis) or absent (<5  % of lysis). We estimated 
variability among the PBMC lytic activities by the coef-
ficient of variation (CV  %), calculated as the standard 
deviation of cell lysis values among all the PBMC samples 
tested divided by the mean and multiplied by 100.
Statistical analysis
Deviation from the Hardy–Weinberg Equilibrium (HWE) 
was analyzed with the Pearson Chi square test by using the 
de Finetti program (http://ihg2.helmholtz-muenchen.de/cgi-
bin/hw/hwa1.pl). A P value <0.05 indicates a lack of HWE.
The comparison of genotype and allele frequencies 
between groups, as well as the association between gen-
otype frequency, clinical-pathological parameters and 
response to trastuzumab were performed by the Pearson 
Chi square test or the Fisher’s exact test, as appropriate. 
For the correlation test between response to trastuzumab 
and cytotoxicity (both basal and trastuzumab-medi-
ated), the Bonferroni correction for three comparisons 
(indicated as Pc), that would require a P value <0.017 to 
reject the null hypothesis, was applied. The comparison 
between basal cell lysis and trastuzumab-mediated lysis 
was performed using a paired Student’s t test.
All statistical tests were two-sided and they were car-
ried out using the SPSS package (version 19.0 for Win-
dows). Statistical significance was accepted for any P 
value <0.05.
Results
Frequencies of FcγRIIIA and FcγRIIA polymorphisms 
in HER‑2 positive BC patients and in control subjects
In this study, we analysed FcγRIIIA 158V>F and FcγRIIA 
131H>R variants in 58 Italian subjects including 25 
HER-2 positive BC patients. Out of these latter, 15 were 
in the neoadjuvant (NEO) setting and 10 in the meta-
static (MTS) setting. Thirty-three healthy control women 
(CTR), matched for age, were also investigated. The main 
characteristics of patients are summarized in Table 2.
Page 5 of 14Boero et al. J Transl Med  (2015) 13:324 
NEO and MTS patients showed similar frequencies 
of FcγRIIIA genotypes (P =  0.763), as well as of alleles 
(P  =  0.815; data not shown), as previously reported 
[17].
Regarding the FcγRIIA SNP, the NEO patients 
showed similar allele frequencies as compared to 
the MTS patients (P  =  0.817, data not shown) but a 
lower frequency of both homozygous genotypes and 
a higher frequency of the heterozygous genotype (20 
vs 40 % H/H, 26.7 vs 40 % R/R and 53.3 vs 20 % H/R), 
although this difference was not statistically significant 
(Table 3). The frequency of FcγRIIIA and FcγRIIA gen-
otypes and alleles of BC patients did not significantly 
differ from those of healthy age-matched CTR when 
considered either separately (NEO vs CTR genotypes, 
P  =  0.751 and P  =  0.836, respectively; NEO vs CTR 
alleles, P = 0.716 and P = 0.563, respectively); MTS vs 
CTR genotypes, P = 0.416 and P = 0.202, respectively; 
MTS vs CTR alleles, P = 0.961 and P = 0.812, respec-
tively) or grouped together with CTR, as reported in 
Table 3.
Control women did not show significantly different 
FcγRIIIA and FcγRIIA genotype frequencies from those 
previously reported for the Italian healthy subjects [7, 
22]. Moreover, no deviation from the Hardy–Weinberg 
equilibrium was observed for any of the polymorphisms 
in BC patients and CTR.
Table 2 Patient characteristics and  response to  trastu-
zumab
NEO neoadjuvant, MTS metastatic, ER estrogen receptor, PGR progesterone 
receptor (the cut-off value for ER and PGR positivity was ≥1 % of 
tumor cells with nuclear staining)
* Visceral with or without non visceral metastatic sites
NEO setting n (%) MTS setting n (%)
Number of patients 15 (100) 10 (100)
Median age, years (range) 44.1 (29–81) 57.4 (40–91)
 ≤50 8 (53.3) 4 (40.0)
 >50 7 (46.7) 6 (60.0)
Menopausal status
 Pre 8 (53.3) 4 (40.0)
 Post 7 (46.7) 6 (60.0)
Hormonal status
 Either ER+ or PgR+ 8 (53.3) 6 (60.0)
 ER−/PgR− 7 (46.7) 4 (40.0)
Number of metastatic sites
 1 – 5 (50.0)
 ≥2 – 5 (50.0)
Metastatic sites
 Non visceral – 3 (30.0)
 Visceral* – 7 (70.0)
Response to trastuzumab
 Complete response 12 (80.0) 3 (30.0)
 Partial response 3 (20.0) 4 (40.0)
 Stable disease – 3 (30.0)
Table 3 Genotypic and allelic frequencies of FcγRIIIA and FcγRIIA polymorphisms in breast cancer patients and healthy 
controls
Genotyping of FcγRIIIA 158V>F was performed by a newly developed PSQ method after pre-amplification of FcγRIIIA gene. Genotyping of FcγRIIA 131H>R 
was performed by T-ARMS PCR and SBT. Conventionally, the 158V>F variant corresponds to the G>T SNP [i.e. guanine corresponding to valine (V) and thymine 
corresponding to phenylalanine (F)] and the 131H>R SNP corresponds to the A>G SNP [i.e. adenine corresponding to histidine (H) and guanine corresponding to 
arginine (R)]
Comparison of FcγR genotypic and allelic frequencies between patients and control subjects was estimated using the Pearson’s χ2  test (P* value) and the Fisher’s test 
(P° value), respectively. Statistical significance: P < 0.05
NEO neoadjuvant, MTS metastatic, CTR controls, HWE Hardy–Weinberg equilibrium. HWE was tested by the Pearson’s χ2 test (P < 0.05 indicates lack of HWE)
Genotypes n (%) P* Alleles n (frequency) P°
NEO (n = 15) MTS (n = 10) CTR (n = 33) NEO (2n = 30) MTS (2n = 20) CTR (2n = 66)
FcγRIIIA 158V>F FcγRIIIA 158V>F
 V/V 4 (26.7) 3 (30.0) 6 (18.2) 0.741  V 13 (0.43) 8 (0.40) 26 (0.39) 0.934
 V/F 5 (33.3) 2 (20.0) 14 (42.4)  F 17 (0.57) 12 (0.60) 40 (0.60)
 F/F 6 (40.0) 5 (50.0) 13 (39.4)
 HWE P = 0.213 P = 0.065 P = 0.522
FcγRIIA 131H>R FcγRIIA 131H>R
 V/V 3 (20.0) 4 (40.0) 9 (27.3) 0.499  H 14 (0.47) 10 (0.50) 35 (0.53) 0.843
 V/F 8 (53.3) 2 (20.0) 17 (51.5)  R 16 (0.53) 10 (0.50) 31 (0.47)
 F/F 4 (26.7) 4 (40.0) 7 (21.2)
 HWE P = 0.782 P = 0.058 P = 0.845
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Analysis of trastuzumab‑mediated ADCC in BC patients
We investigated whether PBMCs, ex  vivo isolated from 
NEO and MTS BC patients before receiving trastu-
zumab, could be activated by the in vitro addition of tras-
tuzumab to elicit ADCC upon interaction with HER-2 
expressing BC cells. To this aim, PBMCs were used in 
a conventional cytolytic assay (at different E:T ratios) 
against the three BC cell lines SKBR3, MCF-7 and BT474, 
expressing different levels of reactivity with trastuzumab, 
as shown by a titration assay using this mAb at differ-
ent concentrations (from 2 to 2 ×  10−4  µg/ml). In par-
ticular, at 0.02 µg/ml the flow cytometry profiles showed 
that SKBR3 expressed a high reactivity with trastuzumab, 
BT474 expressed an intermediate reactivity and MCF-7 
expressed a low reactivity with trastuzumab (Fig. 1). This 
is consistent with previous reports showing SKBR3 as a 
high HER-2-expressing cell line and MCF-7 as a low or 
HER-2-negative cell line [23–25].
The cytolytic assays (ADCC) were performed at a 
constant concentration of 2  µg/ml of trastuzumab or 
medium alone (basal cytotoxicity) and results were esti-
mated as mean percentage of specific cell lysis. This 
antibody concentration corresponds to one of the low-
est concentration of trastuzumab found in patient serum 
during treatment (data not shown). Trastuzumab did not 
elicit ADCC of the HER-2 negative K562 cell line used as 
internal negative control (data not shown).
The results showed that PBMCs from the MTS 
patients killed BC cells more efficiently than PBMCs 
from the NEO patients, at all the E:T ratios both in the 
absence and in the presence of trastuzumab (Fig.  2). 
For instance, at 20:1 E:T ratio, the basal cytotoxicity 
observed for SKBR3, BT474 and MCF-7 was of 18, 8, 
5 % for MTS patients and of 10, 4, 7 % for NEO patients, 
whereas in the presence of trastuzumab the percentage 
of lysis was 35, 24, 22  % in the MTS cohort compared 
Fig. 1 Reactivity of trastuzumab with BC cell lines. Flow cytometric profiles of SKBR-3, BT474 and MCF-7 cell lines stained with serial dilutions (from 
2 to 2 × 10−4 µg/ml) of trastuzumab in a titration assay. The solid line histogram represents the HER-2 staining with trastuzumab and the dotted line 
histogram represents the negative staining with Alexafluor 647-conjugated goat anti-human IgG secondary antibody. Numbers within the quadrants 
represent values of MRFI
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to 22, 12, 18 % observed in NEO patients, respectively. 
ADCC was statistically significant at almost all the E:T 
ratios in both MTS and NEO patients (P values ranging 
from 0.017 to 0.021 with SKBR-3, from 0.002 to 0.012 
with MCF-7, P value =  0.038 with BT474 for MTS; P 
values at all E:T ratios ranging from <0.001 to 0.010 
with all cell lines for NEO). The ADCC degree of NEO 
and MTS patients mainly reflected the intensity of the 
cell line reactivity with trastuzumab: i.e. higher ADCC 
degree was observed with the SKBR3 cell line, followed 
by the BT474 and the MCF-7 cell lines. This finding 
was also confirmed in a cohort of healthy donors (not 
shown).
Correlation of FcγRIIIA and FcγRIIA genotypes with the 
ADCC activity of PBMCs from BC patients in the NEO 
setting
The results of the PBMC-mediated ADCC were then 
evaluated according to the FcγRIIIA and FcγRIIA 
gene polymorphisms. Considering the low number of 
patients within the two BC subgroups, we compared 
results obtained for the wild type FcγRIIIA 158 V/V and 
FcγRIIA 131H/H genotypes with those obtained for the 
mutated 158F (F/V together with F/F) and 131R (R/H 
together with R/R) carrier genotypes, respectively.
The cytolytic assays performed with the NEO patients 
showed that trastuzumab triggered PBMCs derived from 
the FcγRIIIA 158V/V carriers (hereafter 158V/V carri-
ers) to a statistically significant ADCC of SKBR3, BT474 
and MCF-7 cell lines at high (20:1) E:T ratio (P = 0.022, 
P  =  0.042 and P  =  0.038, respectively; Fig.  3a–c). Sig-
nificant ADCC was also observed at 10:1 E:T ratio with 
SKBR3 and BT474 cell lines (P =  0.023 and P =  0.048, 
respectively).
PBMCs derived from the FcγRIIIA 158F carriers (here-
after 158F carriers) elicited a statistically significant 
ADCC of SKBR3 and BT474 cell lines at 20:1 E:T ratio 
(P  =  0.009 and P  =  0.016, respectively) and ADCC of 
MCF-7 also at lower E:T ratios (P = 0.012, P = 0.039 and 
P =  0.019 at 20:1, 10:1 and 5:1 E:T ratios, respectively) 
(Fig. 3a–c).
The NEO patients carrying the 158 V/V variant showed 
a more pronounced ADCC against SKBR3 and BT474 
target cell lines at all the E:T ratios, as compared to the 
158F carriers, although this difference was not statisti-
cally significant (Fig. 3a, b).
The enhancement of basal lysis induced by the 158 V/V 
carriers was independent from the reduction of HER-2 
expression on target cells, whereas the one induced by 
the 158F carriers was slightly decreasing with the reduc-
tion of HER-2 expression (Additional file 1).
Concerning the FcγRIIA polymorphism, PBMCs 
derived from the FcγRIIA 131H/H carrier (hereaf-
ter 131H/H carriers) NEO patients elicited significant 
ADCC of SKBR3, BT474 and MCF-7 cell lines at an E:T 
ratio of 20:1 (P = 0.010, P = 0.029 and P = 0.049, respec-
tively; Fig.  3d–f), whereas for PBMCs derived from the 
131R carriers (hereafter 131R carriers), significant ADCC 
of the three cell lines was observed from 20:1 to 5:1 E:T 
ratios (P values ranging from P  =  0.007 to P  =  0.047; 
Fig. 3d–f).
The 131H/H carriers elicited higher ADCC degrees as 
compared to the 131R carriers against all three cell lines, 
but this difference did not reach statistical significance.
The enhancement of basal lysis induced by the 131H/H 
carriers was independent from HER-2 expression on tar-
get cells, whereas the one induced by the 131R carriers 
was decreasing with the reduction of HER-2 expression 
Fig. 2 Basal and trastuzumab-mediated cytotoxicity of BC cell lines induced by PBMCs derived from BC patients in the NEO and MTS setting. 
PBMCs were analyzed for their cytolytic activity in an ADCC assay using trastuzumab (2 µg/ml) and SKBR3, BT474 and MCF-7 cell lines at differ-
ent effector to target cell ratios (E:T = 2:1, 5:1, 10:1, 20:1). PBMCs were incubated with target cells in medium alone (BASAL) or in the presence of 
trastuzumab (ADCC). Results are expressed as % of 51Cr specific release and are the mean ± SD of experiments with 10 MTS and 15 NEO patients. 
NEO neoadjuvant, MTS metastatic, ADCC antibody-dependent cellular cytotoxicity. Asterisks on the bars indicate statistically significant ADCC at the 
specified E:T ratio evaluated using a paired Student’s t test (see “Results” for P values)
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(Additional file 1). Examples of ADCC and basal lysis for 
each NEO patient are provided against the MCF-7 cell 
line in Additional file 2.
All these findings demonstrate that, in the NEO 
patients, both the FcγRIIIA 158F and FcγRIIA 131R 
carrier genotypes can efficiently induce ADCC also 
at low E:T ratios and that different HER-2 expression 
levels on tumor target cells can affect the intensity 
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Fig. 3 Basal and trastuzumab-mediated cytotoxicity of BC cell lines induced by PBMCs derived from NEO patients according to the FcγRIIIA 158V>F 
and FcγRIIA 131R>H genotypes. PBMCs from NEO patients were analyzed for their cytolytic activity in an ADCC assay using trastuzumab (2 µg/
ml) and SKBR3 (a, d), BT474 (b, e) and MCF-7 (c, f) cell lines at different effector to target cell ratios (E:T = 2:1, 5:1, 10:1, 20:1). PBMCs were incubated 
with target cells in medium alone (BASAL) or in the presence of trastuzumab (ADCC). Results are expressed as % of 51Cr specific release and are the 
mean of experiments with NEO patients at each E:T ratio. CV % was calculated as the standard deviation of cell lysis values among all the PBMC 
samples tested divided by the mean and multiplied by 100. CV at 20:1 E:T ratio for SKBR3: ADCC = 86 %, BASAL = 146 %; for BT474: ADCC = 98 %, 
BASAL = 222 %; for MCF-7: ADCC = 103 %, BASAL = 239 %. a–c V/V carriers (n = 4) and F carriers (n = 9) refer to PBMCs from patients carrying 
the FcγRIIIA (158 V/V) wild type genotype and the heterozygous (V/F) together with the mutated (F/F) genotype, respectively, when incubated 
with target cells in the absence of trastuzumab. Likewise, V/V carriers + Trast and F carriers + Trast, respectively, are refered to PBMCs, showing the 
genotypes described above, incubated in the presence of trastuzumab. d–f H/H carriers (n = 3) and R carriers (n = 10) refer to PBMCs from patients 
carrying the FcγRIIIA (131H/H) wild type genotype and the heterozygous (H/R) together with the mutated (R/R) genotype, respectively, when 
incubated with target cells in the absence of trastuzumab. Likewise, H/H carriers + Trast and R carriers + Trast, respectively, are referred to PBMCs, 
showing the genotypes described above, incubated in the presence of trastuzumab. Asterisks on the curves indicate significant ADCC at the speci-
fied E:T ratio evaluated using a paired Student’s t test (see “Results” for P values). NEO neoadjuvant, ADCC antibody-dependent cellular cytotoxicity, 
Trast trastuzumab
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Correlation of FcγRIIIA and FcγRIIA genotypes with the 
ADCC activity of PBMCs from BC patients in the MTS 
setting
The cytolytic assays performed with the MTS patients 
show that trastuzumab triggered PBMCs derived from 
the FcγRIIIA158F carriers to a significant ADCC of 
SKBR3 and MCF-7 target cells at any of the E:T ratios 
tested (P values ranging from 0.015 to 0.032 and from 
0.009 to 0.013, respectively; Fig.  4a, c). In the case of 
BT474, a trend toward a statistically significant ADCC 
was observed only at the 20:1 E:T ratio (P  =  0.083; 
Fig.  4b) due to the high variability of ADCC levels 
observed among patients. In contrast, PBMCs from the 
158  V/V carriers did not elicit significant ADCC at any 
E:T ratio with the cell lines tested.
The 158F carrier PBMCs showed a more pronounced 
ADCC as compared to the 158V/V carriers, at all the E:T 
ratios, with SKBR3 and BT474 target cells, but not with 
MCF-7 target cells (Fig. 4; Additional file 1).
The enhancement of basal lysis induced by the 158F 
carriers, in the presence of trastuzumab, decreased 
with the reduction of HER-2 expression on target 
cells, whereas the one induced by the 158  V/V carriers 
increased with the reduction of HER-2 surface expres-
sion, at any of the E:T ratios (Additional file 1).
Concerning the FcγRIIA polymorphism, PBMCs derived 
from the 131H/H carrier or 131R carrier MTS patients 
triggered statistically significant ADCC against BT474 or 
MCF-7 cell lines at 20:1 E:T ratio (P = 0.028 and P = 0.034, 
respectively) (Fig.  4e, f ). The 131H/H carriers induced a 
more pronounced ADCC as compared to the 131R carri-
ers against SKBR3 and MCF-7 (Fig.  4d, f ), although this 
difference did not reach statistically significance.
The enhancement of basal lysis induced by both the 
131H/H and 131R carriers, in the presence of trastu-
zumab, was independent from the reduction of HER-2 
expression on target cells, at any of the E:T ratios (Addi-
tional file 1). Examples of ADCC and basal lysis for each 
MTS patient are provided against the MCF-7 cell line in 
Additional file 3.
Taken together, these findings demonstrate that the 
FcγRIIIA158F carrier genotype can behave as a favoura-
ble genotype for promoting ADCC. In addition, different 
HER-2 expression levels on tumor target cells can affect 
the intensity of ADCC triggered by the FcγRIIIA 158 V/V 
and 158F carriers. These findings were confirmed in a 
cohort of healthy donors (Additional file 4).
Correlation of basal cytotoxicity and ADCC with prognostic 
factors and response to trastuzumab
Taking into account that cell cytotoxicity was scored as 
present (≥5 % of lysis) or absent (<5 % of lysis), we found 
that, in the NEO patients, the pathological complete 
response (pCR) to trastuzumab significantly correlated 
with an increased frequency of patients showing ADCC 
(Table  4). Indeed, the number of patients with present 
cytotoxicity in the absence of trastuzumab (BASAL) sig-
nificantly increased after addition of trastuzumab (from 
18.2 to 90.9 % with MCF-7 cell line; P = 0.002; Bonfer-
roni corrected Pc = 0.006). A noticeable increase was also 
observed with BT747 (from 11.1 to 66.7  %) and SKBR3 
(from 36.4 to 81.8  %), although it was not statistically 
significant.
When basal cytotoxicity and ADCC were correlated 
to the partial response (pPR) no statistically significant 
results were observed. This analysis was limited by the 
extremely low number of patients (n = 2 or 3 depending 
on the cell line used as target; Table 4). Also in the MTS 
subgroup, the frequency of patients with present cyto-
toxicity in the CR subgroup increased, upon addition of 
trastuzumab, when the MCF-7 cell line was used as tar-
get (data not shown).
These results suggest that ADCC can play a role in the 
response to trastuzumab and that this role can be bet-
ter detectable when using, as target cells, a BC cell line 
showing low trastuzumab reactivity, such as MCF-7.
We did not find any significant correlation between 
FcγRIIIA and FcγRIIA gene polymorphisms, basal cell 
lysis and ADCC with patient age, life status (alive or dead) 
and prognostic factors including menopausal status, hor-
monal receptor status, number and sites of metastases, 
that were found to display significant association with 
FcγRIIIA/IIA polymorphisms in previous studies [18]. 
Finally, we did not observe any significant correlations 
between FcγRIIIA or FcγRIIA SNPs and patient response 
to trastuzumab.
Discussion
Trastuzumab is a human mAb that specifically binds the 
extracellular domain of HER-2 receptor expressed by BC 
cells. Trastuzumab is currently used as a single agent [26] 
and in combination with chemotherapy [27–29] for the 
treatment of women with either early [30] or advanced 
HER-2 overexpressing BC [27, 28]. The principal mech-
anisms of action of trastuzumab include direct growth 
inhibition leading to apoptosis of tumor cells, comple-
ment-dependent cytotoxicity and ADCC by NK cells, 
monocytes and granulocytes [31].
It has been previously shown that functional FcγR 
SNPs can regulate the trastuzumab-mediated ADCC and 
predict the clinical outcome of BC patients treated with 
trastuzumab-based therapy [7, 17, 32].
In this study, we investigated in  vitro the ADCC elic-
ited by PBMCs from NEO and MTS BC patients and 
correlated its extent with FcγRIIIA 158V>F and FcγRIIA 
131H>R genotypes and response to trastuzumab.
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We found that the FcγRIIIA 158F and/or the FcγRIIA 
131R genotypes, that are commonly reported as unfa-
vourable genotypes not only in BC [7, 32] but also in 
other tumours [10, 11], may actually behave as favour-
able genotypes. Indeed, the 158F and 131R genotypes 
were able to elicit a stronger ADCC, as compared to 
the 158V/V and 131H/H genotypes, which remained 
significant also at low E:T ratios. In addition, in some 
instances, only the 158F and 131R genotypes showed sig-
nificant ADCC. The MCF-7 cell line has previously been 
found weakly- or not-expressing HER-2 [24, 25, 33, 34] 
so that it has been used as a negative control for trastu-
zumab-mediated ADCC [34]. In our experimental sys-



































































































































































Fig. 4 Basal and trastuzumab-mediated cytotoxicity of BC cell lines induced by PBMCs derived from the MTS patients according to the FcγRIIIA 
158V>F and FcγRIIA 131R>H genotypes. PBMCs from MTS patients were analyzed for their cytolytic activity in an ADCC assay using trastuzumab 
(2 µg/ml) and SKBR3 (a, d), BT474 (b, e) and MCF-7 (c, f) cell lines at different effector to target cell ratios (E:T = 2:1, 5:1, 10:1, 20:1). PBMCs were 
incubated with target cells in medium alone (BASAL) or in the presence of trastuzumab (ADCC). Results are expressed as % of 51Cr specific release 
and are the mean of experiments with MTS patients at each E:T ratio. CV % was calculated as the standard deviation of cell lysis values among 
all the PBMC samples tested divided by the mean and multiplied by 100. CV at 20:1 E:T ratio for SKBR3: ADCC = 72 %, BASAL = 114 %; for BT474: 
ADCC = 81 %, BASAL = 108 %; for MCF-7: ADCC = 78 %, BASAL = 140 %. a–c V/V carriers (n = 3) and F carriers (n = 6) refer to PBMCs from patients 
carrying the FcγRIIIA (158 V/V) wild type genotype and the heterozygous (V/F) together with the mutated (F/F) genotype, respectively, when incu-
bated with target cells in the absence of trastuzumab. Likewise, V/V carriers + Trast and F carriers + Trast, respectively, are referred to PBMCs, show-
ing the genotypes described above, incubated in the presence of trastuzumab. d–f H/H carriers (n = 4) and R carriers (n = 5) refer to PBMCs from 
patients carrying the FcγRIIIA (131H/H) wild type genotype and the heterozygous (H/R) together with the mutated (R/R) genotype, respectively, 
when incubated with target cells in the absence of trastuzumab. Likewise, H/H carriers + Trast and R carriers + Trast, respectively, are referred to 
PBMCs, showing the genotypes described above, incubated in the presence of trastuzumab. Asterisks on the curves indicate significant ADCC at the 
specified E:T ratio evaluated using a paired Student’s t test (see “Results” for P values). MTS metastatic, ADCC antibody-dependent cellular cytotoxic-
ity, Trast trastuzumab
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trastuzumab by flow cytometry, as compared to SKBR3 
and BT474 cell lines that showed high reactivity. There-
fore, our ADCC results with MCF-7 cell line may have 
implications in trastuzumab-based therapy because they 
suggest that also tumor cells which are not HER-2-am-
plified and display low levels of HER-2 expression can be 
efficiently targeted with trastuzumab.
In the NEO patients, the FcγRIIIA 158V/V genotype 
correlated with a statistically significant ADCC in all cell 
lines tested, at high E:T ratios, whereas this correlation 
was not observed in the MTS patients at any E:T ratio. 
The FcγRIIA131H/H genotype correlated with a statis-
tically significant ADCC at high E:T ratios with two or 
three cell lines depending on the setting, NEO or MTS, 
analyzed.
Although different effector cell types within PBMCs 
can engage trastuzumab, we here chose to evaluate the 
overall lytic activity of PBMCs isolated before starting 
trastuzumab therapy in order to mimic the ADCC condi-
tion that may occur in vivo. For this reason, we evaluated 
the FcγRIIIA and FcγRIIA gene polymorphisms that are 
respectively involved in the activation of the NK cell pop-
ulation and other accessory cells of the immune system. 
We found a broad interindividual variability of ADCC 
levels among patients which might be related to the FcγR 
genotypes, as well as to the proportion and/or lytic effi-
ciency of effector cells present in the PBMCs samples.
The ADCC variability was indicated by the high CV 
values that we observed among all the PBMC samples 
tested (CVs ranging from 72 to 103 %, depending on the 
BC setting and target cell line). Remarkably, we noticed 
that the variability was more pronounced in the spon-
taneous (basal) cytotoxicity (CVs ranging from 108 to 
239  %), as compared to ADCC, condition that was also 
observed among healthy individuals (Additional file  4 ). 
To explain the lower CV values in trastuzumab-mediated 
cell lysis, it is conceivable that the addition of trastu-
zumab to the cytolytic assay provides an optimal stimulus 
to trigger the activation of cytolytic effector cells. Indeed, 
the FcγRIIIA engagement with trastuzumab resulted in 
a homogeneous triggering of FcγRIIIA +  PBMCs abro-
gating the individual specific feature of spontaneous lysis 
of each donor and pointing out their maximal cytolysis. 
Indeed, only using trastuzumab we could find a biologi-
cally significant degree of target cell lysis.
Altogether, the MTS patients showed higher levels of 
ADCC against all BC cell lines used as targets, as com-
pared to the NEO patients, thus confirming that ADCC 
can be efficient also in the advanced stage of BC, as 
reported in previous studies [7, 35]. A possible explana-
tion for the higher ADCC in MTS patients may be the 
different immunologic context under which immune 
cells become activated in the two patient settings. In par-
ticular, the immune response elicited by BC in the NEO 
patients might be confined to the tumour microenviron-
ment whereas that elicited in the MTS patients might be 
systemic resulting from a generalized and more potent 
immune cell stimulation due to the spread of BC to 
other parts of the body. Indeed, we found that the ADCC 
observed in MTS patients was similar, in intensity and 
variability, to that observed in healthy donors suggest-
ing that MTS patients are in a different activation state as 
Table 4 Correlation of basal cytotoxicity and ADCC with response to trastuzumab of neoadjuvant breast cancer patients
PBMCs were analyzed for their cytolytic activity in an ADCC assay using trastuzumab (2 µg/ml) and SKBR3, BT474 and MCF-7 cell lines at 20:1 effector to target cell 
ratio. PBMCs were incubated with target cells in medium alone (BASAL) or in the presence of trastuzumab (ADCC). Results are expressed as number and percentages 
(in brackets) of patients showing basal or trastuzumab-mediated cytotoxicity (cut off: >5 %)
Comparison of BASAL cytotoxicity and ADCC was estimated using the Fisher’s test (P value) (significance level <0.05) and further adjusted with Bonferroni correction 
for multiple comparisons (Pc value) in the indicated patients
NEO neoadjuvant, ADCC antibody-dependent cellular cytotoxicity, pPR pathological partial response, pCR pathological complete response
NEO patients pPR (n = 3) P pCR (n = 12) P Pc
Cytotoxicity Cytotoxicity
BASAL ADCC BASAL ADCC
SKBR3 n = 3 n = 3 n = 11 n = 11
Present 1 (33.3) 3 (100.0) 0.400 4 (36.4) 9 (81.8) 0.080 0.240
Absent 2 (66.7) 0 (–) 7 (63.6) 2 (18.2)
BT474 n = 2 n = 2 n = 9 n = 9
Present 0 (–) 1 (50.0) 0.400 1 (11.1) 6 (66.7) 0.050 0.147
Absent 2 (100.0) 1 (50.0) 8 (88.9) 3 (33.3)
MCF-7 n = 2 n = 2 n = 11 n = 11
Present 0 (–) 2 (100.0) 0.333 2 (18.2) 10 (90.9) 0.002 0.006
Absent 2 (100.0) 0 (–) 9 (81.8) 1 (9.1)
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compared to NEO patients. Thus, the different efficacy of 
MTS and NEO cytolytic activity may be due to intrinsic 
biological characteristics of the immune cells (activation 
state, lytic efficiency, different cell number) rather than 
to the effects of clinical-pathological parameters. In both 
BC subgroups, the entity of ADCC reflected the HER-2 
expression levels as the highest absolute values were 
observed with the SKBR3 cell line.
In NEO and MTS subgroups the enhancement of basal 
lysis induced by the FcγRIIIA158F carriers was depend-
ent on HER-2 expression, whereas the one induced by 
the 158V/V carriers was dependent on HER-2 expression 
only in the MTS subgroup. Concerning the FcγRIIA, the 
enhancement of basal lysis induced by the H/H carriers 
was independent from HER-2 expression in both MTS 
and NEO subgroups and the one induced by the 131R 
carrier was dependent on HER-2 expression in NEO, but 
not in MTS patients.
In summary, these data demonstrate a different behav-
iour, in respect to the FcγR genotypes and ADCC extent, 
of BC cell lines expressing different HER-2 levels. These 
levels might be representative of the tumour and intra-
tumoral heterogeneity of HER-2 expression that has 
recently been reported in a proportion of breast cancers 
(36). This heterogeneity is clinically relevant for its asso-
ciation with the response to HER-2-targeted therapy.
To date, there are still conflicting reports in the lit-
erature concerning the role of FcγR polymorphisms 
in the clinical outcome of trastuzumab-treated BC 
patients. Even the largest retrospective analysis per-
formed by Hurwitz et  al. in the adjuvant and meta-
static settings does not seem to completely exclude a 
contribution of FcγR polymorphisms and ADCC/FcγR 
engagement to the outcome of trastuzumab-treated 
patients [18]. Thus, the conflicting results may derive 
from different factors including ethnical differences 
in the SNP frequency, genotyping problems due to the 
high homology between FcγR members, differences in 
the modalities of therapeutic use of trastuzumab (i.e. 
NEO, MTS or adjuvant setting) or in the chemother-
apy regimen.
In addition, only few reports analyzed the associa-
tion of FcγR polymorphisms with ADCC intensity and 
with clinical outcome [7, 8]; other reports analyzed only 
the association of FcγR polymorphisms with clinical 
response without taking into account the ADCC [17, 18, 
32], or the association between ADCC and response to 
trastuzumab without considering the FcγR gene poly-
morphisms [34, 35]. Although performed in a quite small 
number of patients, our study correlates FcγR gene poly-
morphisms to the ADCC extent in combination with the 
HER-2 expression levels on tumor target cells. Similarly, 
this study also correlates FcγR polymorphisms to the 
basal lysis extent. Indeed, in both NEO and MTS patients 
the 158 V/V carriers showed, in some instances, a more 
pronounced lysis as compared to that of the 158F car-
riers, although in MTS patients with BT474 cell line we 
found that 158F carrier showed a more efficient basal 
lysis than 158 V/V. However, this difference was not sta-
tistically significant and may depend on intrinsic features 
of each patient.
Our results demonstrate a statistically significant cor-
relation of the ADCC degree with the complete response 
of NEO patients to trastuzumab. In particular, the fre-
quency of patients with positive ADCC was signifi-
cantly increased using the MCF-7 cell line as target, as 
compared to patients without ADCC; this suggests that 
also small variations in the percent of cell lysis observed 
in vitro might contribute to the induction of a complete 
response in vivo.
It is of note that the increase of patients showing cyto-
toxicity was observed with the MCF-7 cell line suggesting 
that the use of low-HER-2-expressing cells might be use-
ful for testing of ADCC.
Even if further investigations in larger cohort studies 
are required to confirm our findings, these results pro-
vide additional information for a better understanding 
of the role of FcγR gene polymorphisms/ADCC in tras-
tuzumab-treated BC; this study might improve the test-
ing of patient ADCC in order to identify subgroups of 
patients who might benefit from trastuzumab treatment.
Conclusions
In our experimental system, we could detect that unfa-
vourable FcγRIIIA158F carrier or FcγRIIA131R carrier 
genotypes may actually behave as favourable genotypes.
Despite the limitation due to the small number of 
patients enrolled, our findings would suggest that in the 
in vitro assays for the ADCC activity of patients eligible 
for trastuzumab therapy it might be useful to include a 
panel of BC cell lines showing different HER-2 expression 
levels, as they may reflect the in vivo HER-2 heterogene-
ity in different tumor areas [36].
Additional files
Additional file 1: Table S1. Enhancement of basal lysis of different BC 
cell lines induced in the presence of trastuzumab.
Additional file 2: Figure S1 Basal and trastuzumab-mediated cytotoxic-
ity of MCF-7 cell line induced by PBMCs derived from the NEO individual 
patients.
Additional file 3: Figure S2. Basal and trastuzumab-mediated cytotoxic-
ity of MCF-7 cell line induced by PBMCs derived from the MTS individual 
patients.
Additional file 4: Figure S3. Basal and trastuzumab-mediated cytotoxic-
ity of BC cell lines induced by PBMCs derived from healthy donors.
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